Search for Clinical Trial Results
Marginal Zone Lymphoma - 6 Studies Found
Status | Study |
Terminated |
Study Name: Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma Condition:
|
Terminated |
Study Name: Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Treating Patients With Stage III or Stage IV Follicular Lymphoma or Marginal Zone Lymphoma Condition: Lymphoma Date: 2008-10-12 Interventions:
|
Terminated |
Study Name: Salvage Therapy With High Dose Oral Clarithromycin in Relapsed or Refractory Extranodal Marginal Zone Lymphoma Condition: Lymphoma Date: 2012-01-06 Interventions: Drug: clarithromycin, oral, high dose 2 g/day clarithromycin (once a day) for 14 days followed by 7 days |
Completed |
Study Name: Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia Condition:
|
RECRUITING |
Study Name: FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role Condition: Marginal Zone Lymphoma Date: 2024-10-22 |
RECRUITING |
Study Name: MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL) Condition: Follicular Lymphoma and Marginal Zone Lymphoma Date: 2024-10-22 Interventions: 1000mg /dose for 12 cycles(28 days) and a total of 11 doses :the first Cycle(Day1,Day15), the 2nd-8th Cycles(Day 1 every cycle);the 9th-12nd Cycl |